Veridian Research Library

BPC-157: A Source-Verified Research Dossier

A structured, evidence-tiered review of BPC-157 — what it is, its proposed mechanisms and the uncertainty around them, preclinical and limited human findings, limitations, and investigational/regulatory status — drawn from primary literature and regulatory records.

TB-500: A Source-Verified Research Dossier

A structured, evidence-tiered review of TB-500 (Ac-LKKTETQ) — what it is, its relationship to thymosin beta-4, the critical distinction between the fragment and the parent peptide, preclinical and human evidence, limitations, and regulatory status — drawn from primary literature and regulatory records.

Wolverine (BPC-157 + TB-500): A Source-Verified Research Dossier

An evidence-tiered dossier on the Wolverine research blend (BPC-157 + TB-500) — what it is, how constituent evidence is structured, the critical distinction between individual-constituent research and the combined formulation, limitations, and regulatory status.

GHK-Cu: A Source-Verified Research Dossier

An evidence-tiered review of GHK-Cu (glycyl-L-histidyl-L-lysine complexed with Cu2+) — its copper-binding biology, extracellular-matrix and skin research, the distinction between biochemical/preclinical and human cosmetic/clinical evidence, limitations, and regulatory status.

MOTS-c: A Source-Verified Research Dossier

An evidence-tiered review of MOTS-c — the mitochondrial-derived peptide, its metabolic signaling (AMPK), preclinical evidence, the limited human evidence, limitations, and regulatory status.

NAD+: A Source-Verified Research Dossier

An evidence-tiered review of NAD+ (nicotinamide adenine dinucleotide) — a cellular coenzyme, its redox and sirtuin-substrate roles, the distinction between NAD+ itself and its precursors (NR, NMN), preclinical and human evidence, limitations, and regulatory status.

SS-31 (Elamipretide): A Source-Verified Research Dossier

An evidence-tiered review of SS-31/elamipretide — the mitochondria-targeted tetrapeptide, cardiolipin binding, preclinical evidence, human trials, the 2025 FDA accelerated approval for Barth syndrome (FORZINITY), and the distinction between the approved drug and Veridian's research-grade material.

Ipamorelin: A Source-Verified Research Dossier

An evidence-tiered review of ipamorelin — the synthetic pentapeptide growth-hormone secretagogue, its GHS-R1a (ghrelin receptor) pharmacology, GH-axis biology, the distinction between biological effects and clinical benefit, and regulatory status.

Epitalon: A Source-Verified Research Dossier

An evidence-tiered review of Epitalon (AEDG) — what it is, its pineal/telomerase biology, cell and animal findings, the limited and largely extract-based human data, and current regulatory status — distinguishing Epitalon from the parent pineal extract Epithalamin.

DSIP (Delta Sleep-Inducing Peptide): A Source-Verified Research Dossier

An evidence-tiered review of DSIP — its 1970s discovery, the unresolved receptor and mechanism question, early animal and human sleep findings, proposed neuroendocrine/stress effects, and current regulatory status — without implying that its name proves it reliably induces sleep in humans.

KPV: A Source-Verified Research Dossier

An evidence-tiered review of KPV — its relationship to alpha-MSH / melanocortin biology, its proposed anti-inflammatory signaling, intestinal and epithelial model research, and current regulatory status — distinguishing cell, animal, and human evidence and not implying clinical anti-inflammatory efficacy where human evidence is absent.

ARA-290 (Cibinetide): A Source-Verified Research Dossier

An evidence-tiered review of ARA-290 (cibinetide) — an erythropoietin-derived, nonerythropoietic 11-amino-acid peptide — its innate repair receptor hypothesis, preclinical findings, the specific human clinical trials in sarcoidosis neuropathy and diabetic macular edema, and current regulatory status: investigational and not FDA-approved.

Thymosin Alpha-1 (Thymalfasin): A Source-Verified Research Dossier

An evidence-tiered review of thymosin alpha-1 (thymalfasin, Zadaxin) — its thymic immune biology, clinical investigation in hepatitis and as a vaccine adjuvant, and a complicated international regulatory history: approved in 30+ countries but NOT FDA-approved in the United States — carefully distinguishing it from thymosin beta-4 and TB-500.

Neuroscience 12 min read

Cerebrolysin: A Source-Verified Research Dossier

An evidence-tiered review of Cerebrolysin — a porcine-brain-derived peptide and amino-acid preparation (not a single synthetic peptide) — its neuroscience research in stroke, traumatic brain injury, and cognitive/neurodegenerative contexts, the systematic-review and Cochrane limitations that identify mixed findings and methodological concerns, and regulatory status by jurisdiction (not FDA-approved in the U.S.).

Tesamorelin: A Source-Verified Research Dossier

An evidence-tiered review of tesamorelin — a synthetic GHRH (growth hormone-releasing hormone) analogue, the FDA-approved pharmaceutical Egrifta for HIV-associated lipodystrophy, its phase-3 human clinical evidence, the rebound after discontinuation, and WADA prohibited status — distinguishing the approved drug from Veridian's research-grade material.

PT-141 / Bremelanotide: A Source-Verified Research Dossier

An evidence-tiered review of PT-141 (bremelanotide) — a synthetic cyclic heptapeptide melanocortin receptor agonist, the FDA-approved pharmaceutical Vyleesi for acquired, generalized HSDD in premenopausal women, its phase-3 evidence, the earlier discontinued intranasal erectile-dysfunction program (transient BP elevations), and limitations — distinguishing the approved drug from Veridian's research-grade PT-141.

Oxytocin: A Source-Verified Research Dossier

An evidence-tiered review of oxytocin — a hypothalamic nonapeptide acting at the OXTR receptor, the FDA-approved obstetric pharmaceutical Pitocin for labor induction/postpartum hemorrhage, the extensive investigational intranasal social-cognition and psychiatric literature (with mixed/null replication), and the clear separation of approved obstetric use from unapproved CNS indications — distinguishing the approved drug from Veridian's research-grade material.

Kisspeptin: A Source-Verified Research Dossier

An evidence-tiered review of kisspeptin — the KISS1-encoded endogenous ligand of the GPR54/KISS1R receptor and a key upstream regulator of hypothalamic GnRH neurons — its metastasis-suppressor origin, pubertal and reproductive-axis biology, early-phase human kisspeptin-54 IV research, and clear distinction from HCG (which acts at the gonadal LH receptor). Not FDA-approved.

5-Amino-1MQ: A Source-Verified Research Dossier

An evidence-tiered review of 5-amino-1MQ (5-amino-1-methylquinolinium) — a small-molecule (not a peptide) inhibitor of nicotinamide N-methyltransferase (NNMT), with preclinical evidence in 3T3-L1 adipocyte and diet-induced-obese mouse models. No human clinical trials; not FDA-approved.

HGH (Human Growth Hormone / Somatropin): A Source-Verified Research Dossier

An evidence-tiered review of HGH (human growth hormone / somatropin) — a 191-amino-acid protein hormone (not a small peptide), with multiple FDA-approved recombinant products for defined endocrine indications, WADA-prohibited status, and no approved use for general anti-aging — distinguishing the approved products from Veridian's research-grade material and from small-peptide GH secretagogues (ipamorelin, tesamorelin).

Neuroscience 11 min read

Dihexa: A Source-Verified Research Dossier

An evidence-tiered review of Dihexa — an angiotensin-IV-derived investigational compound studied in relation to the HGF/c-Met system — describing the published HGF-dependent c-Met activation, hippocampal spinogenesis/synaptogenesis, and procognitive effects in experimental models, the later APP/PS1 mouse work, and the absence of convincing controlled human efficacy data. Not FDA-approved; preclinical/investigational.

Neuroscience 11 min read

Semax: A Source-Verified Research Dossier

An evidence-tiered review of Semax — the synthetic ACTH(4–7)-Pro-Gly-Pro heptapeptide — covering the older human clinical literature in ischemic stroke, substantial experimental/mechanistic work, and later animal transcriptomic studies. States plainly that Semax is not FDA-approved in the U.S. and that evidence for generalized cognition, performance, ADHD, anti-aging, or healthy-person nootropic use is not established by robust U.S.-standard clinical trials.

Neuroscience 11 min read

Selank: A Source-Verified Research Dossier

An evidence-tiered review of Selank — the synthetic tuftsin-derived heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro — covering the limited human literature (including an older randomized comparison in generalized anxiety/neurasthenia), mechanistic work on enkephalin metabolism and neurotransmitter systems, and experimental anxiolytic effects. States plainly that Selank is not FDA-approved, human evidence is limited, the published clinical literature is geographically concentrated and small, and the evidence does not establish broad cognitive enhancement or treatment of every anxiety disorder.

Metabolic & Mitochondrial Research 13 min read

Tirzepatide: A Source-Verified Research Dossier

An evidence-tiered review of tirzepatide — a dual GIP receptor and GLP-1 receptor agonist — describing its FDA-approved pharmaceutical products (Mounjaro for type 2 diabetes; Zepbound for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity), the SURPASS/SURMOUNT phase-3 evidence, major safety/regulatory context, and the strict distinction between the FDA-approved products and Veridian's research-grade material.

Neuroscience 10 min read

Pinealon: A Source-Verified Research Dossier

An evidence-tiered review of Pinealon — the synthetic tripeptide Glu-Asp-Arg (EDR), described as a peptide bioregulator — covering experimental findings (oxidative-stress models, ROS-related effects, cell viability, and proliferative/cell-cycle signaling). States plainly that no established human neuroprotection, cognitive enhancement, anti-aging, dementia treatment, or longevity extension is supported. Not FDA-approved.

Glutathione: A Source-Verified Research Dossier

An evidence-tiered review of glutathione — the endogenous tripeptide glutamate-cysteine-glycine (GSH) — describing its established biological role in cellular redox balance, antioxidant defense, glutathione peroxidase systems, and detoxification/conjugation biology, the human oral glutathione biomarker studies (with outcomes varying by formulation, endpoint, route, and study design), and FDA safety concerns regarding compounded injectable glutathione. Does not imply glutathione injection is FDA-approved for general wellness.

Cosmetic / Skin Research 10 min read

AHK-Cu: A Source-Verified Research Dossier

An evidence-tiered review of AHK-Cu — the copper-binding tripeptide alanine-histidine-lysine complexed with Cu2+ — distinct from GHK-Cu. Covers copper-binding biology, dermal papilla cells, hair-follicle-related experimental research, and VEGF-related findings where supported. AHK-Cu is not FDA-approved; human clinical evidence is limited compared with established pharmaceutical therapies, and cosmetic or hair-growth claims do not exceed the actual evidence.

CJC-1295 No DAC: A Source-Verified Research Dossier

An evidence-tiered review of CJC-1295 No DAC (modified GRF 1-29) — a GHRH analogue distinct from original CJC-1295 with DAC. Explains the nomenclature issue accurately: literature on DAC-containing CJC-1295 is not direct evidence for the No-DAC material. Separates endogenous GHRH physiology, pharmaceutical/experimental GHRH analogs, and evidence applicable to the Veridian compound. Not FDA-approved; no established anti-aging/bodybuilding/performance indication.

CJC + Ipamorelin Blend: A Source-Verified Research Dossier

An evidence-tiered review of the CJC + Ipamorelin blend (CJC-1295 No DAC + Ipamorelin) that strictly distinguishes direct blend evidence (none found), ingredient-level evidence (CJC/GHRH-receptor and Ipamorelin/ghrelin-receptor, studied independently), and mechanistic rationale (a hypothesis only). States plainly that no controlled human trial has evaluated the exact finished blend. Does not claim the combination builds muscle, burns fat, improves recovery, reverses aging, improves sleep, or increases athletic performance. Not FDA-approved.

Sexual & Reproductive Health Research 12 min read

HCG (Human Chorionic Gonadotropin): A Source-Verified Research Dossier

An evidence-tiered review of human chorionic gonadotropin (hCG) — a glycoprotein hormone (not a short peptide) that signals through the LH/CG receptor and has FDA-approved pharmaceutical products for defined medical indications. Distinguishes legitimate approved pharmaceutical hCG from Veridian's research-use material, discusses established reproductive-endocrinology and pregnancy biology without treatment instructions, and addresses the historical hCG weight-loss diet accurately per FDA records (hCG not demonstrated to produce weight loss beyond calorie restriction; hCG weight-loss products subject to regulatory warnings).

KLOW Blend: A Source-Verified Research Dossier

An evidence-tiered review of the KLOW blend (GHK-Cu + BPC-157 + TB-500 + KPV) that strictly distinguishes direct blend evidence (none found), ingredient-level evidence (each constituent with its own evidence tier, covered in its own Veridian dossier), and mechanistic rationale (a hypothesis only). States prominently that no peer-reviewed controlled human trials of KLOW as this exact formulation were found. Does not claim proven tissue repair, systemic healing, injury recovery, anti-inflammatory synergy, skin rejuvenation, or joint repair for the complete blend.

GLOW Blend: A Source-Verified Research Dossier

An evidence-tiered review of the GLOW blend (GHK-Cu + BPC-157 + TB-500) that strictly distinguishes direct blend evidence (none found), ingredient-level evidence (each constituent with its own evidence tier, covered in its own Veridian dossier), and mechanistic rationale (a hypothesis only). States prominently that no peer-reviewed controlled human trials of GLOW as this exact formulation were found. Does not claim clinically established skin rejuvenation, collagen restoration, wound healing, anti-aging, hair growth, systemic recovery, or cosmetic improvement for the finished blend based merely on constituent research.

Neuroscience 10 min read

P21 (P021): A Source-Verified Research Dossier

An evidence-tiered review of P21 (also designated P021 in the literature) — a synthetic neurotrophic peptide derived from the active region of ciliary neurotrophic factor (CNTF), studied in preclinical neuroscience models for neurogenesis, synaptic plasticity, and cognitive function. States plainly that all available evidence is preclinical (cell and animal models); no human clinical trials have been conducted. Does not claim established treatment of Alzheimer's disease, dementia, traumatic brain injury, cognitive impairment, neurodegeneration, or memory loss. Not FDA-approved.

Sexual & Reproductive Health Research 9 min read

Prostamax: A Source-Verified Research Dossier

An evidence-tiered review of Prostamax — a synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Pro / KEDP) from the Khavinson peptide bioregulator family, studied in preclinical prostate tissue models. States plainly that the available evidence is preclinical (animal and in-situ models); no controlled human clinical trials of Prostamax as a standalone product have been identified in the peer-reviewed literature. Does not claim established treatment of BPH, prostatitis, prostate cancer, or sexual dysfunction. Not FDA-approved.